Reaction
Diabetic Retinal Oedema reporting signals
As of the last recalculation, Diabetic Retinal Oedema appears in 503 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 654.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 229 | 654.4 | 660.2 |
| Aflibercept | 85 | 135.5 | 135.8 |
| Faricimab | 16 | 84.3 | 84.5 |
| Insulin Glulisine | 15 | 62.9 | 63.0 |
| Bevacizumab | 108 | 45.7 | 45.7 |
| Cefazolin Sodium | 12 | 42.2 | 42.2 |
| Cefazolin | 9 | 41.5 | 41.6 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 15 | 27.3 | 27.3 |
| Triamcinolone Acetonide | 18 | 25.0 | 25.0 |
| Insulin Lispro | 50 | 16.5 | 16.5 |